Home Translational Medicine Biomarkers Looking Beyond NIPT, Natera Eyes Cancer, Transplant Testing Growth

Natera labs CROPPED11111 — In an interview with GEN during the recent J.P. Morgan 39th Healthcare Conference, CEO Steve Chapman said Natera’s priorities for 2021 include expansions in noninvasive prenatal testing (NIPT), transplant rejection testing, minimal residual disease (MRD) cancer testing, and pharmaceutical business for its Signatera™ circulating tumor DNA (ctDNA) cancer test. [Natera]

Looking Beyond NIPT, Natera Eyes Cancer, Transplant Testing Growth

CEO eyes broader revenue base, pan-cancer future for Signatera

By Alex Philippidis

January 27, 2021

In an interview with GEN during the recent J.P. Morgan 39th Healthcare Conference, CEO Steve Chapman said Natera’s priorities for 2021 include expansions in noninvasive prenatal testing (NIPT), transplant rejection testing, minimal residual disease (MRD) cancer testing, and pharmaceutical business for its Signatera™ circulating tumor DNA (ctDNA) cancer test. [Natera]

In an interview during the recent J.P. Morgan 39th Healthcare Conference, Chapman said Natera aims to build on its 2020 accomplishments, which included processing a record 1 million tests, successfully launching Signatera, and surpassing growth goals set before COVID-19 for its Prospera™ donor-derived, cell-free DNA (cfDNA) transplant assessment test . . .